Oncology and Hematology - Global Oncology Academy

Episodes 81-96 of 296

Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Project Oncology®
Nephrotoxicity in the Crosshairs: Optimizing Renal Cancer Care with Kidney Preservation
Poster Pearl: A 2-Biomarker Class MCED Test Delivers High Specificity and Sensitivity
Poster Pearl: A 2-Biomarker Class MCED Test Delivers High Specificity and Sensitivity
Project Oncology®
Poster Pearl: A 2-Biomarker Class MCED Test Delivers High Specificity and Sensitivity
- Brian P. McDonough, MD, FAAFP
- Frank Diehl, PhD
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Project Oncology®
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Future Directions: Targeting LAG-3 in Melanoma Treatment
Future Directions: Targeting LAG-3 in Melanoma Treatment
MinuteCE®
Future Directions: Targeting LAG-3 in Melanoma Treatment
0.75 program credits
- Hussein Tawbi, MD, PhD
0.75 program credits
Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints
Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints
MinuteCE®
Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints
0.75 program credits
- Hussein Tawbi, MD, PhD
0.75 program credits
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
MinuteCE®
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
0.75 program credits
- Allison Betof Warner, MD, PhD
0.75 program credits
Analyzing Key Data from LAG-3 Combinations in the Treatment of Metastatic Melanoma
Analyzing Key Data from LAG-3 Combinations in the Treatment of Metastatic Melanoma
MinuteCE®
Analyzing Key Data from LAG-3 Combinations in the Treatment of Metastatic Melanoma
0.75 program credits
- Hussein Tawbi, MD, PhD
0.75 program credits
First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
MinuteCE®
First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
0.75 program credits
- Allison Betof Warner, MD, PhD
0.75 program credits
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
MinuteCE®
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
0.75 program credits
- Allison Betof Warner, MD, PhD
0.75 program credits
MinuteCE®
Leveraging LAG-3: Innovative Immunotherapy Combinations for First-Line Metastatic Melanoma Treatment
0.75 credits 7 episodes
- Allison Betof Warner, MD, PhD
- Hussein Tawbi, MD, PhD
0.75 credits 7 episodes
Patient Case: Tailoring First-Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status
Patient Case: Tailoring First-Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status
MinuteCE®
Patient Case: Tailoring First-Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status
0.75 program credits
- Hussein Tawbi, MD, PhD
0.75 program credits
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
MinuteCE®
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
1.25 program credits
- Yelena Janjigian, MD
- Samuel J. Klempner, MD
1.25 program credits
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
MinuteCE®
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
1.25 program credits
- Yelena Janjigian, MD
- Samuel J. Klempner, MD
1.25 program credits
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
MinuteCE®
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
MinuteCE®
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Project Oncology®
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC

Previous
1
2
…
4
5
6
7
8
…
18
19
Next

6/11